Comparative Proteomic Analysis of the Secretome of Control and BRAF/MEK Inhibitor-Resistant Melanoma Cells — VialBase Research
Thymosin Beta-4 identified in secretome of BRAF/MEK inhibitor-resistant melanoma cells
- Thymosin Beta-4 identified in secretome of BRAF/MEK inhibitor-resistant melanoma cells
- Treatment-resistant cells affect tumor microenvironment through secreted factors
- Many upregulated proteins in resistant cells relate to cell adhesion and actin cytoskeleton
- Tβ4 as actin-sequestering protein may play role in cancer cell migration
Summary
Proteomic analysis comparing secretomes of BRAF/MEK inhibitor-resistant melanoma cells versus non-resistant controls. Identified significant differences in protein composition, with many upregulated proteins in resistant cells directly related to cancer progression, cell adhesion, and actin cytoskeleton dynamics. Thymosin Beta-4 was identified among the secreted factors.
Key Findings
- Resistant melanoma cells secrete different protein profiles compared to non-resistant cells
- Actin cytoskeleton-related proteins (including Tβ4) are upregulated in resistant cells
- The secretome of resistant cells can influence other cancer cells and the tumor microenvironment
- GO analysis identified cell adhesion and actin cytoskeleton as enriched pathways
Relevance to TB-500
This study raises important safety considerations for TB-500 use. The presence of Tβ4 in drug-resistant melanoma secretomes suggests that Tβ4’s actin-sequestering and cell migration-promoting properties could theoretically support tumor progression or drug resistance. While this does not prove exogenous TB-500 promotes cancer, it reinforces the precautionary principle that TB-500 should not be used in patients with active malignancy.
Citation
Simiczyjew A, et al. J Proteome Res. 2026;25(4):2084-2097. PMID: 41966639
See Also
- Parent compound: TB-500